Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: capecitabine|DRUG: fulvestrant
Sponsor: Accelerated Community Oncology Research Network
Collaborators: Hoffmann-La Roche|AstraZeneca